PRMT7

Across TCGA pan-cancer cohorts, PRMT7 RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of PRMT7’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where PRMT7 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PRMT7 is over-expressed in tumor, although a few such as KICH and THCA show the opposite, repressed pattern.

KIRC, COAD, and KICH are the cancer types where PRMT7 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRMT7 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+0.475	<.001	12	view →
COAD	Female	All	+1.034	<.001	11	view →
KICH	Female	All	−0.726	<.001	9	view →
THCA	All	All	−0.270	<.001	9	view →
LIHC	Female	II,III,IV	+0.896	<.001	8	view →
HNSC	Male	III,IV	+0.449	<.001	8	view →
STAD	Male	II,III,IV	+0.842	<.001	6	view →
BLCA	All	All	+0.462	.004	6	view →
CHOL	Male	All	+1.451	<.001	5	view →
LUAD	Female	All	+0.346	<.001	5	view →
LUSC	All	All	+0.306	<.001	4	view →
ESCA	All	II,III,IV	+0.890	.035	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

PRMT7–KIRC

Open the KIRC breakdown →